Clinical Trials Logo

Alzheimer Disease clinical trials

View clinical trials related to Alzheimer Disease.

Filter by:

NCT ID: NCT00452504 Completed - Alzheimer Disease Clinical Trials

Single Ascending Dose Study of SRA-444 in Healthy Subjects

Start date: February 2007
Phase: Phase 1
Study type: Interventional

This is a first-in-humans study of SRA-444. This study will provide an initial assessment of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SRA-444 (SR formulation) after administration of ascending single oral doses to healthy adult subjects.

NCT ID: NCT00448799 Completed - Alzheimers Disease Clinical Trials

Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls

Start date: March 2007
Phase: Phase 1
Study type: Interventional

The underlying goal of this study is to assess 123-I AV83 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of AD research participants and age- and gender-matched healthy subjects.

NCT ID: NCT00443417 Completed - Alzheimer's Disease Clinical Trials

A Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease

Start date: April 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find optimistic dose and to evaluate the efficacy and safety of SK-PC-B70M in patients with mild to moderate Alzheimer's disease.

NCT ID: NCT00443014 Completed - Alzheimer Disease Clinical Trials

The Dementia Study in Northern Norway

Start date: June 2003
Phase: Phase 4
Study type: Interventional

The Dementia Study in Northern Norway is an open controled intervention trial carried out in nine rural municipalities, five of which allocated to intervention and four to control. A RCT with donepezil and placebo is superimposed on all patients included in the study. In this way the study has a 2x2 factorial design. The outcome measures are changes in cognitive performance and ADL function measured by standardized cognitive and neuropsychological tests every four months during a one-year follow-up. The main goal of this study is to examine the effect of systematically and individually adjusted stimulation therapy on cognitive function in patients having recent diagnoses of Alzheimer´s disease (AD). A secondary goal is to examine whether or not ChEI has an additional effect on cognitive function superimposed on stimulation therapy. From January 2006 to 31th March 2008 187 patients with a recent diagnosis of dementia were included. Patients were recruited by GPs in routine practice (n=87) and by a population based screening (n=100).Screening recruited younger patients with a higher MMSE-score, and relatively more men. All over, women were older and at a more serious disease stage. After age adjusting significantly more women were living single and required more supports from the community nursery.

NCT ID: NCT00440050 Completed - Alzheimer's Disease Clinical Trials

DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease

DHA
Start date: February 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether chronic DHA (Docosahexaenoic Acid) supplementation slows the progression of cognitive and functional decline in mild to moderate Alzheimer's disease (AD).

NCT ID: NCT00439166 Completed - Alzheimer's Disease Clinical Trials

Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid

Start date: February 2007
Phase: Phase 3
Study type: Interventional

This study will determine if biomarkers found in the cerebrospinal fluid of people with Alzheimer's disease, are affected by treatment with two common antibiotics, doxycycline and rifampicin, suggesting a disease-modifying effect of those treatments.

NCT ID: NCT00439010 Completed - Alzheimers Disease Clinical Trials

Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects

Start date: February 2007
Phase: Phase 1
Study type: Interventional

The underlying goal of this study is to assess 123-I AV39 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of AD research participants and age- and gender-matched healthy subjects.

NCT ID: NCT00438568 Completed - Clinical trials for Mild Cognitive Impairment

SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days)

SNIFF 120
Start date: June 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out if insulin, when administered as a "nasal spray" into the nasal passages, improves memory in adults with mild cognitive impairment (MCI) or Alzheimer's disease.

NCT ID: NCT00432081 Completed - Alzheimer Disease Clinical Trials

Effect of Indomethacin on the Progression of Alzheimer's Disease

Start date: May 2000
Phase: Phase 3
Study type: Interventional

The purpose of this study is determine whether indomethacin is able to retard disease progression in patients with mild to moderate Alzheimer's disease.

NCT ID: NCT00428389 Completed - Alzheimer's Disease Clinical Trials

Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease

Start date: January 2007
Phase: Phase 3
Study type: Interventional

This study was designed to evaluate the safety and tolerability of switching from donepezil to an initial dose of 5cm^2 rivastigmine patch formulation in patients with probable Alzheimer's Disease (MMSE 10-24). The study included a 5-week, open-label, randomized period followed by a 20-week open-label extension period. Patients were randomized to either an immediate switch from donepezil to rivastigmine patch formulation or to a switch to rivastigmine patch formulation following a 7-day withdrawal period.